title: Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
authors.affiliation: Institute of Pathology, Safdarjang Hospital Campus, New Delhi, India.
authors.forename: D
authors.initials: D
authors.lastname: Kumar
authors.forename: V
authors.initials: V
authors.lastname: Ramesh
authors.forename: S
authors.initials: S
authors.lastname: Verma
authors.forename: M
authors.initials: M
authors.lastname: Ramam
authors.forename: P
authors.initials: P
authors.lastname: Salotra
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D001706:Biopsy; D005260:Female; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D007898:Leishmaniasis, Visceral / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011247:Pregnancy; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine; D000666:Amphotericin B; D000967:Antimony Sodium Gluconate